1789. Use of Pharmacokinetics/Pharmacodynamics to Optimize Lead Candidate Section
Session: Symposium: Decreasing the Risk of Antibacterial Drug Development through Pharmacokinetics/Pharmacodynamics
Monday, October 27, 2008: 12:00 AM
Room: Constitution E (Grand Hyatt)
David Melnick, MD, Astra Zeneca Pharmaceuticals, Wilmington, DE and  D. Melnick,
AstraZeneca Role(s): Employee, Employee, Received: Salary.

David A. Melnick, MD
Dr. Melnick joined AstraZeneca in June 2001 and is currently Medical Science Director for Infection Emerging Products. He received his medical training at Columbia University, followed by Residency in Internal Medicine at The New York Hospital-Cornell Medical Center. Following a Fellowship in Infectious Disease at Yale University, he held faculty positions at the Boston University School of Medicine and the National Institute of Allergy and Infectious Diseases. Prior to joining AstraZeneca he served as Director of HIV Clinical Research at Kaiser Permanente with a faculty appointment at Georgetown University. Research interests have included the cell biology of human phagocytic cells, the use of cytokines in the treatment of immunodeficiency syndromes, the application of viral drug resistance testing to the treatment of HIV infection, and the prevention of resistance to antimicrobial therapy.